As the United States pharma develops it has been trying to make substantial drug manufactures that can aid chronic disease prevention or cure and to some extent their efforts are noteworthy and some rare times even absolutely amazing.
The U.S. Food and Drug Administration (FDA) approved a second drug that aims to prevent HIV/AIDS in men and transgender women, according to a Rutgers press release. The new drug, Discover, enters the pharmaceutical market along with Truvada, the current HIV prevention standard, according to the release. Both drugs are made by the same company, Gilead. “Descovy is yet another tool that we have in our arsenal to end HIV transmission — a desire that numerous states, national and global organizations and governments share,” said Perry Halkitis, dean of the Rutgers School of Public Health. When the FDA approves a drug for HIV prevention, it becomes known as pre-exposure prophylaxis (PrEP), according to the release. This past week, California signed a bill allowing PrEp to be sold without a prescription, becoming the first state to do so, according to an article from NPR.
With the rise in drug variety for HIV prevention purpose, there are possible options for the people who could not use the previous drug due to health complications. HIV is a deadly disease and has been taking a huge toll on lives for a long time and now these prevention drugs are challenging the disease which once we thought was impossible. The need for breakthrough drugs is rising as you read so we might as well make it worth it.
Tags : U.S. Food and Drug Administration, FDA, Rutgers School of Public Health, HIV prevention,